WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

The test identifies viral genetic material in blood samples, giving outbreak teams a faster, quality-assessed route to confirm cases. In a response where days matter, the progress is not abstract: lab capacity in affected areas has reportedly scaled from roughly 200–400 tests per day at limited sites to more than 2,000 tests per day across 10 laboratories.

A diagnostic milestone with operational value

WHO’s Emergency Use Listing is not a marketing badge. It is a mechanism for assessing the quality, safety, and performance of essential health products using available evidence, with minimum international standards and the needs of low- and middle-income countries in view.

That matters because Ebola Bundibugyo virus disease is being managed in emergency conditions, not ideal laboratory conditions. WHO says the listed molecular test detects Bundibugyo virus by identifying its genetic material in blood. In practical terms, that can help clinicians confirm infection rapidly and accurately, support earlier care decisions, and strengthen surveillance.

The timing is notable. WHO Director-General Dr Tedros Adhanom Ghebreyesus declared a public health emergency of international concern on May 17, 2026, over an outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo, with cases in Uganda. Less than two weeks later, WHO called for manufacturers of in vitro diagnostics for Bundibugyo virus to submit expressions of interest for Emergency Use Listing.

That sequence shows the machinery of outbreak response doing what it is designed to do: define the need, evaluate the tools, then create a procurement pathway that governments and UN agencies can use with more confidence.

The numbers show why testing capacity is central

WHO describes the current event as the largest recorded outbreak of Ebola disease caused by Bundibugyo virus. As of the WHO update, the Democratic Republic of the Congo alone had reported 1,406 laboratory-confirmed cases and 438 deaths.

In that context, diagnostic throughput becomes a hard constraint. Before the expansion, testing capacity was concentrated in a limited number of sites, mainly the Institut National de Recherche Biomédicale in Kinshasa and Goma, with an estimated combined capacity of about 200–400 tests per day. With support from WHO and Africa CDC, that has expanded to a network of 10 laboratories across affected provinces, with reported capacity above 2,000 tests per day.

That is the kind of metric that changes response geometry. More testing capacity can shorten the distance between suspected case, confirmed diagnosis, clinical care, and surveillance action. It also reduces reliance on scarce centralized capacity when an outbreak is expanding across provinces.

WHO Assistant Director-General Dr Yukiko Nakatani framed the listing in those terms: emergency response requires speed, but also confidence that products meet standards for quality, safety, and performance. That is the core point for readers tracking scientific progress: the breakthrough is not just the existence of a test, but the validation and access pathway around it.

What to watch next

This listing is probably not the endpoint. WHO says additional applications for Bundibugyo virus in vitro diagnostics are under review. In parallel, WHO and Africa CDC, with partners including PATH, FIND, and CHAI, and support from Unitaid, are setting up a joint validation platform to evaluate diagnostic products in outbreak settings.

The platform is expected to assess a range of tools: laboratory-based molecular tests, near-point-of-care molecular tests, and antigen rapid diagnostic tests. That mix is important. Central molecular testing can deliver accuracy and scale, but outbreak control often benefits from tools that can move closer to patients and field teams.

For the broader public, the practical takeaway is simple: watch for quality-assured diagnostics, not just claims of speed. In fast-moving outbreaks, the most useful innovation is the one that can be trusted, procured, deployed, and measured under pressure. WHO’s first Emergency Use Listing for a Bundibugyo virus molecular test is a concrete step in that direction.